When Do You Notice Weight Loss on Wegovy — and What Shapes the Timeline?

Why do most people not see major results in the first few weeks?

Wegovy's dose schedule is intentional. Treatment starts at 0.25 mg weekly, a level designed to let your body adjust rather than drive significant weight loss. Nausea and digestive discomfort are most common in the first four weeks, and the starter dose reduces that risk. At this stage, the most useful signal is not the scales but whether your hunger between meals has started to quiet down.

By weeks four to eight (when the dose moves to 0.5 mg) many people notice they are leaving food on the plate or finding their usual portion uncomfortably large. That behavioural shift is the drug working. Weight change tends to lag slightly behind it. If you are weighing yourself daily, you will see natural fluctuation that can obscure a real downward trend; a weekly weigh-in at the same time of day gives a cleaner picture.

There is a detailed look at how long before you notice weight loss on Wegovy that maps the early-weeks experience in more depth, which is worth reading alongside this page.

When does weight loss typically become noticeable to others?

The question of when weight loss becomes visible to other people is different from when it shows up on your scales. A general rule of thumb in clinical practice is that changes in clothing fit or facial appearance tend to become visible to others once someone has lost roughly 5–10% of their starting body weight. At a starting weight of 100 kg, that is 5–10 kg, a threshold many Wegovy users reach somewhere between months two and four, depending on the dose they have reached and their individual response.

The STEP 1 trial, published in the New England Journal of Medicine, showed that participants on 2.4 mg semaglutide lost an average of around 15% of body weight over 68 weeks. That figure covers the full treatment period; the curve is steepest in months three to nine, when most people are on or approaching the maintenance dose. Progress then slows and often plateaus as the body adapts.

People who want to understand how the pattern unfolds over time may find it helpful to read about when you start to see weight loss on Wegovy, which focuses on month-by-month patterns rather than the headline trial figure.

What slows the timeline, and is a slower response a sign the medicine is not working?

Several things influence pace. The dose matters most: the 2.4 mg maintenance dose produces meaningfully greater appetite suppression than the lower titration doses, so people who tolerate the full schedule well tend to see faster loss. Those who need to slow their titration due to side effects (perfectly reasonable, and something a prescriber will guide) simply take longer to reach the dose where the medicine is most effective.

Diet quality makes a significant difference. Wegovy reduces hunger, but it does not override dietary patterns entirely. People who use the appetite reduction as a scaffold for higher-protein, higher-fibre eating tend to lose more, and more sustainably, than those whose diet does not change in composition. The NHS semaglutide guidance notes that the medicine should be used alongside a reduced-calorie diet and increased physical activity, not instead of them.

A slower response in the early months is not necessarily a sign that Wegovy is not working. Individual metabolic variation is real. If after six months on the maintenance dose less than 5% of starting body weight has been lost, that is the clinical threshold at which continuing the prescription is reviewed, a point covered in NICE's recommendation for semaglutide (TA875). That review happens with your prescriber, not by stopping unilaterally.

For context on the broader cost and access picture, Wegovy pricing in the UK sets out what a private prescription typically involves, including what a legitimate service includes in the price.

Does the new 7.2 mg dose change the timeline?

In April 2026 the MHRA approved a dedicated single-dose 7.2 mg Wegovy pen, the highest maintenance dose yet licensed in the UK, for adults with a BMI of 30 or above. Trial data reported average weight loss of around 20.7% over 72 weeks at this dose, approaching the results seen with tirzepatide 15 mg in head-to-head evidence. That is a meaningful step up from the 2.4 mg figure, and it suggests that for eligible patients the ceiling on what Wegovy can achieve is higher than earlier data implied.

The titration schedule still starts at 0.25 mg regardless of which pen a patient will eventually reach. Many patients ask when they start seeing weight loss on Wegovy at the higher doses, and the honest answer is that the difference accumulates over months as the higher maintenance dose takes effect rather than compressing the early stages. Whether 7.2 mg is appropriate is a clinical decision made at review, not something to request at the outset. You can read about when you start noticing weight loss on Wegovy at the higher doses on a dedicated page, and find more detail on when you see weight loss on Wegovy there too.

If you are considering starting treatment, checking your eligibility through a free consultation is the first step. A GPhC-registered prescriber at our pharmacy reads every assessment the same day, your consultation goes to a named clinician, not into an automated queue. Once approved, your pen ships via DPD in plain, unbranded packaging and arrives the next working day, tracked to your door.